SRPT Annual CAPEX
$87.34 M
+$55.09 M+170.83%
31 December 2023
Summary:
As of January 20, 2025, SRPT annual capital expenditures is $87.34 million, with the most recent change of +$55.09 million (+170.83%) on December 31, 2023. During the last 3 years, it has risen by +$5.14 million (+6.26%). SRPT annual CAPEX is now at all-time high.SRPT CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Quarterly CAPEX
$37.26 M
+$8.10 M+27.76%
30 September 2024
Summary:
As of January 20, 2025, SRPT quarterly capital expenditures is $37.26 million, with the most recent change of +$8.10 million (+27.76%) on September 30, 2024. Over the past year, it has increased by +$18.22 million (+95.72%). SRPT quarterly CAPEX is now -12.21% below its all-time high of $42.44 million, reached on March 31, 2024.SRPT Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT TTM CAPEX
$127.91 M
-$3.51 M-2.67%
30 September 2024
Summary:
As of January 20, 2025, SRPT TTM capital expenditures is $127.91 million, with the most recent change of -$3.51 million (-2.67%) on September 30, 2024. Over the past year, it has increased by +$40.57 million (+46.45%). SRPT TTM CAPEX is now -2.67% below its all-time high of $131.42 million, reached on June 30, 2024.SRPT TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +170.8% | +95.7% | +46.5% |
| 3 y3 years | +6.3% | +294.1% | +347.3% |
| 5 y5 years | +42.8% | +294.1% | +347.3% |
SRPT CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +170.8% | -12.2% | +725.3% | -2.7% | +407.6% |
| 5 y | 5-year | at high | +170.8% | -12.2% | +725.3% | -2.7% | +407.6% |
| alltime | all time | at high | >+9999.0% | -12.2% | -2.7% | >+9999.0% |
Sarepta Therapeutics CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $37.26 M(+27.8%) | $127.91 M(-2.7%) |
| June 2024 | - | $29.17 M(-31.3%) | $131.42 M(+9.3%) |
| Mar 2024 | - | $42.44 M(+122.9%) | $120.21 M(+37.6%) |
| Dec 2023 | $87.34 M(+170.8%) | $19.04 M(-53.3%) | $87.34 M(+14.2%) |
| Sept 2023 | - | $40.77 M(+127.1%) | $76.47 M(+69.4%) |
| June 2023 | - | $17.95 M(+87.4%) | $45.16 M(+24.5%) |
| Mar 2023 | - | $9.58 M(+17.3%) | $36.28 M(+12.5%) |
| Dec 2022 | $32.25 M(-21.0%) | $8.17 M(-13.6%) | $32.25 M(+12.8%) |
| Sept 2022 | - | $9.46 M(+4.2%) | $28.60 M(+0.8%) |
| June 2022 | - | $9.08 M(+63.5%) | $28.39 M(+12.6%) |
| Mar 2022 | - | $5.55 M(+22.9%) | $25.20 M(-38.2%) |
| Dec 2021 | $40.80 M(-50.4%) | $4.51 M(-51.1%) | $40.80 M(-37.1%) |
| Sept 2021 | - | $9.24 M(+56.8%) | $64.89 M(-19.8%) |
| June 2021 | - | $5.89 M(-72.1%) | $80.96 M(-14.1%) |
| Mar 2021 | - | $21.15 M(-26.1%) | $94.23 M(+14.6%) |
| Dec 2020 | $82.20 M(+37.9%) | $28.61 M(+13.1%) | $82.20 M(+16.0%) |
| Sept 2020 | - | $25.30 M(+32.0%) | $70.85 M(+28.9%) |
| June 2020 | - | $19.17 M(+110.2%) | $54.98 M(+4.7%) |
| Mar 2020 | - | $9.12 M(-47.2%) | $52.49 M(-12.0%) |
| Dec 2019 | $59.63 M(-2.5%) | $17.26 M(+83.0%) | $59.63 M(-0.5%) |
| Sept 2019 | - | $9.43 M(-43.5%) | $59.94 M(-16.4%) |
| June 2019 | - | $16.68 M(+2.6%) | $71.68 M(+11.0%) |
| Mar 2019 | - | $16.26 M(-7.4%) | $64.58 M(+5.6%) |
| Dec 2018 | $61.16 M(+188.3%) | $17.57 M(-17.0%) | $61.16 M(+27.1%) |
| Sept 2018 | - | $21.17 M(+121.0%) | $48.11 M(+38.7%) |
| June 2018 | - | $9.58 M(-25.4%) | $34.70 M(+22.4%) |
| Mar 2018 | - | $12.84 M(+183.9%) | $28.34 M(+33.6%) |
| Dec 2017 | $21.21 M(+209.0%) | $4.52 M(-41.7%) | $21.21 M(+5.9%) |
| Sept 2017 | - | $7.75 M(+140.3%) | $20.04 M(+49.0%) |
| June 2017 | - | $3.23 M(-43.5%) | $13.45 M(+22.3%) |
| Mar 2017 | - | $5.71 M(+70.7%) | $11.00 M(+60.2%) |
| Dec 2016 | $6.87 M(+42.1%) | $3.35 M(+187.2%) | $6.87 M(+35.8%) |
| Sept 2016 | - | $1.17 M(+49.9%) | $5.05 M(-6.0%) |
| June 2016 | - | $777.00 K(-50.8%) | $5.38 M(-2.0%) |
| Mar 2016 | - | $1.58 M(+2.8%) | $5.49 M(+13.6%) |
| Dec 2015 | $4.83 M(-82.0%) | $1.53 M(+3.1%) | $4.83 M(-28.5%) |
| Sept 2015 | - | $1.49 M(+68.1%) | $6.76 M(-62.8%) |
| June 2015 | - | $886.00 K(-4.0%) | $18.16 M(-17.9%) |
| Mar 2015 | - | $923.00 K(-73.3%) | $22.13 M(-17.5%) |
| Dec 2014 | $26.82 M(+610.6%) | $3.46 M(-73.2%) | $26.82 M(+11.3%) |
| Sept 2014 | - | $12.90 M(+166.0%) | $24.10 M(+87.1%) |
| June 2014 | - | $4.85 M(-13.7%) | $12.88 M(+44.3%) |
| Mar 2014 | - | $5.62 M(+667.8%) | $8.93 M(+136.4%) |
| Dec 2013 | $3.77 M(+229.7%) | $732.00 K(-56.4%) | $3.77 M(+8.9%) |
| Sept 2013 | - | $1.68 M(+87.2%) | $3.47 M(+85.3%) |
| June 2013 | - | $896.00 K(+90.6%) | $1.87 M(+38.2%) |
| Mar 2013 | - | $470.00 K(+11.1%) | $1.35 M(+18.2%) |
| Dec 2012 | $1.15 M(-50.3%) | $423.00 K(+422.2%) | $1.15 M(-24.0%) |
| Sept 2012 | - | $81.00 K(-78.6%) | $1.51 M(-13.7%) |
| June 2012 | - | $379.00 K(+44.7%) | $1.75 M(-21.8%) |
| Mar 2012 | - | $262.00 K(-66.6%) | $2.23 M(-3.2%) |
| Dec 2011 | $2.31 M(+18.0%) | $784.00 K(+145.0%) | $2.31 M(+13.8%) |
| Sept 2011 | - | $320.00 K(-63.0%) | $2.03 M(-7.6%) |
| June 2011 | - | $865.00 K(+157.4%) | $2.19 M(+22.8%) |
| Mar 2011 | - | $336.00 K(-33.5%) | $1.79 M(-8.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | $1.95 M(-2.0%) | $505.00 K(+3.7%) | $1.95 M(-19.1%) |
| Sept 2010 | - | $487.00 K(+6.3%) | $2.42 M(+6.9%) |
| June 2010 | - | $458.00 K(-9.1%) | $2.26 M(+2.6%) |
| Mar 2010 | - | $504.00 K(-47.9%) | $2.20 M(+10.4%) |
| Dec 2009 | $1.99 M(+63.8%) | $967.00 K(+193.0%) | $1.99 M(+36.4%) |
| Sept 2009 | - | $330.00 K(-17.7%) | $1.46 M(+11.4%) |
| June 2009 | - | $401.00 K(+35.5%) | $1.31 M(+11.8%) |
| Mar 2009 | - | $296.00 K(-31.9%) | $1.17 M(-3.5%) |
| Dec 2008 | $1.22 M(-42.8%) | $434.40 K(+140.5%) | $1.22 M(+10.0%) |
| Sept 2008 | - | $180.60 K(-31.3%) | $1.11 M(-30.1%) |
| June 2008 | - | $263.00 K(-22.4%) | $1.58 M(-14.8%) |
| Mar 2008 | - | $339.00 K(+4.8%) | $1.86 M(-12.7%) |
| Dec 2007 | $2.13 M(+46.3%) | $323.60 K(-50.7%) | $2.13 M(+6.2%) |
| Sept 2007 | - | $656.50 K(+22.3%) | $2.00 M(+8.8%) |
| June 2007 | - | $537.00 K(-12.0%) | $1.84 M(+3.8%) |
| Mar 2007 | - | $610.00 K(+205.3%) | $1.77 M(+22.0%) |
| Dec 2006 | $1.45 M(-1.0%) | $199.80 K(-59.6%) | $1.45 M(-20.5%) |
| Sept 2006 | - | $494.20 K(+5.1%) | $1.83 M(+10.5%) |
| June 2006 | - | $470.30 K(+62.5%) | $1.65 M(+11.0%) |
| Mar 2006 | - | $289.50 K(-49.5%) | $1.49 M(+1.5%) |
| Dec 2005 | $1.47 M(+37.1%) | $573.60 K(+78.7%) | $1.47 M(+27.8%) |
| Sept 2005 | - | $321.00 K(+4.9%) | $1.15 M(-10.3%) |
| June 2005 | - | $306.10 K(+14.6%) | $1.28 M(+7.8%) |
| Mar 2005 | - | $267.20 K(+5.2%) | $1.19 M(+11.0%) |
| Dec 2004 | $1.07 M(-34.7%) | $254.10 K(-43.9%) | $1.07 M(-5.0%) |
| Sept 2004 | - | $453.00 K(+111.8%) | $1.13 M(+27.4%) |
| June 2004 | - | $213.90 K(+43.3%) | $884.40 K(-12.6%) |
| Mar 2004 | - | $149.30 K(-51.9%) | $1.01 M(-38.3%) |
| Dec 2003 | $1.64 M(-41.0%) | $310.70 K(+47.6%) | $1.64 M(-23.9%) |
| Sept 2003 | - | $210.50 K(-38.3%) | $2.16 M(-17.7%) |
| June 2003 | - | $341.10 K(-56.1%) | $2.62 M(-3.2%) |
| Mar 2003 | - | $777.60 K(-6.0%) | $2.71 M(-2.6%) |
| Dec 2002 | $2.78 M(-33.5%) | $827.00 K(+22.9%) | $2.78 M(-26.4%) |
| Sept 2002 | - | $672.70 K(+56.9%) | $3.77 M(-4.0%) |
| June 2002 | - | $428.80 K(-49.5%) | $3.93 M(-1.9%) |
| Mar 2002 | - | $849.10 K(-53.4%) | $4.01 M(-4.1%) |
| Dec 2001 | $4.18 M(+413.7%) | $1.82 M(+119.0%) | $4.18 M(+58.4%) |
| Sept 2001 | - | $831.40 K(+64.5%) | $2.64 M(+24.8%) |
| June 2001 | - | $505.40 K(-50.4%) | $2.11 M(+19.0%) |
| Mar 2001 | - | $1.02 M(+263.8%) | $1.78 M(+118.4%) |
| Dec 2000 | $813.20 K(+306.6%) | $280.30 K(-9.0%) | $813.10 K(+28.5%) |
| Sept 2000 | - | $308.00 K(+83.1%) | $632.80 K(+94.8%) |
| June 2000 | - | $168.20 K(+197.2%) | $324.80 K(+107.4%) |
| Mar 2000 | - | $56.60 K(-43.4%) | $156.60 K(-21.7%) |
| Dec 1999 | $200.00 K(-91.3%) | $100.00 K(>+9900.0%) | $200.00 K(0.0%) |
| Sept 1999 | - | $0.00(0.0%) | $200.00 K(-91.7%) |
| June 1999 | - | $0.00(-100.0%) | $2.40 M(0.0%) |
| Mar 1999 | - | $100.00 K(0.0%) | $2.40 M(+4.3%) |
| Dec 1998 | $2.30 M(+666.7%) | $100.00 K(-95.5%) | $2.30 M(-4.2%) |
| Sept 1998 | - | $2.20 M(+1000.0%) | $2.40 M(+700.0%) |
| Dec 1997 | $300.00 K(+200.0%) | $200.00 K(>+9900.0%) | $300.00 K(+200.0%) |
| Sept 1997 | - | $0.00(0.0%) | $100.00 K(0.0%) |
| June 1997 | - | $0.00(-100.0%) | $100.00 K(0.0%) |
| Mar 1997 | - | $100.00 K | $100.00 K |
| Dec 1996 | $100.00 K | - | - |
FAQ
- What is Sarepta Therapeutics annual capital expenditures?
- What is the all time high annual CAPEX for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual CAPEX year-on-year change?
- What is Sarepta Therapeutics quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly CAPEX year-on-year change?
- What is Sarepta Therapeutics TTM capital expenditures?
- What is the all time high TTM CAPEX for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM CAPEX year-on-year change?
What is Sarepta Therapeutics annual capital expenditures?
The current annual CAPEX of SRPT is $87.34 M
What is the all time high annual CAPEX for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual capital expenditures is $87.34 M
What is Sarepta Therapeutics annual CAPEX year-on-year change?
Over the past year, SRPT annual capital expenditures has changed by +$55.09 M (+170.83%)
What is Sarepta Therapeutics quarterly capital expenditures?
The current quarterly CAPEX of SRPT is $37.26 M
What is the all time high quarterly CAPEX for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly capital expenditures is $42.44 M
What is Sarepta Therapeutics quarterly CAPEX year-on-year change?
Over the past year, SRPT quarterly capital expenditures has changed by +$18.22 M (+95.72%)
What is Sarepta Therapeutics TTM capital expenditures?
The current TTM CAPEX of SRPT is $127.91 M
What is the all time high TTM CAPEX for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM capital expenditures is $131.42 M
What is Sarepta Therapeutics TTM CAPEX year-on-year change?
Over the past year, SRPT TTM capital expenditures has changed by +$40.57 M (+46.45%)